Aegerion Pharmaceuticals, Inc. to Present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference

BRIDGEWATER, N.J., Dec. 1, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference in San Francisco. Will Lewis, President of Aegerion, is scheduled to present on Tuesday, December 7, 2010, at 5:30 p.m. EST (2:30 p.m. PST).